Medi Lifestyle, on Jan 4, announced that its indirect wholly owned subsidiary, HealthPro Marketing Sdn Bhd, has signed a distributor agreement with Malaysian Genomics Resource Centre Berhad.
The agreement will see HealthPro Marketing market, sell and distribute Malaysian Genomics’ cell and cell-free products including Mesenchymal Stem Cell-derived Exosomes in Singapore and Cambodia.
The agreement is valid for an initial period of one year and is renewable on an annual basis. Under the agreement, HealthPro Marketing will be granted exclusivity for the sales and distribution of the products subject to certain targets being met.
Malaysian Genomics is a Bursa-listed company that operates the only Bio-Safety Level 2 (BSL-2) laboratories in Southeast Asia. The laboratories are current good manufacturing practice (cGMP)-approved for cell engineering BSL-2 and cGMP certifications. The certifications indicate that a laboratory facility has stringent measures for biocontainment standards and ultra-pure laboratory environments to safely work on human cells.
“Our mission is to improve the quality of life for all. This is why we strive to provide excellent preventive healthcare and patient wellness services. By collaborating with Malaysian Genomics, we are now expanding our business growth into promoting and marketing cell and cell-free therapy products, this leads to continuous growth,” says Dato Ken Low, executive director and CEO of Medi Lifestyle.
“We are excited to have the opportunity to partner with HPM in providing products in support of their preventive health care services. Our laboratory facilities and expertise will be leveraged in this partnership,” adds Dato’ Alvin Nesakumar, executive director of Malaysian Genomics.
See also: Smaller players find own growth niches
Shares in Medi Lifestyle closed flat at 0.8 cent on Jan 4.